Celldex Therapeutics, Inc. (CLDX) Given Buy Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) in a research report released on Tuesday morning. They currently have a $9.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the company. ValuEngine cut Celldex Therapeutics from a sell rating to a strong sell rating in a report on Friday, September 1st. HC Wainwright set a $10.00 target price on Celldex Therapeutics and gave the stock a buy rating in a report on Wednesday, August 9th. BidaskClub cut Celldex Therapeutics from a sell rating to a strong sell rating in a report on Monday, July 24th. Zacks Investment Research cut Celldex Therapeutics from a buy rating to a sell rating in a report on Monday, July 17th. Finally, Aegis reiterated a buy rating on shares of Celldex Therapeutics in a report on Thursday, June 29th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $7.32.

Celldex Therapeutics (CLDX) traded up 3.31% during mid-day trading on Tuesday, reaching $2.81. The company’s stock had a trading volume of 1,189,194 shares. Celldex Therapeutics has a 12 month low of $2.20 and a 12 month high of $5.02. The company’s market cap is $360.64 million. The stock’s 50 day moving average is $2.49 and its 200 day moving average is $2.83.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The firm had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $1.21 million. During the same quarter last year, the business earned ($0.32) earnings per share. The company’s revenue was up 175.5% compared to the same quarter last year. Equities research analysts predict that Celldex Therapeutics will post ($1.04) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/09/27/celldex-therapeutics-inc-cldx-given-buy-rating-at-cantor-fitzgerald.html.

Institutional investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. raised its position in Celldex Therapeutics by 26.2% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 6,000 shares during the last quarter. BB&T Securities LLC acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at approximately $117,000. Voya Investment Management LLC raised its position in Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 7,499 shares during the last quarter. Overbrook Management Corp acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at approximately $139,000. Finally, Pacad Investment Lt

A number of other equities analysts have also recently issued reports on the company. ValuEngine cut Celldex Therapeutics from a sell rating to a strong sell rating in a report on Friday, September 1st. HC Wainwright set a $10.00 target price on Celldex Therapeutics and gave the stock a buy rating in a report on Wednesday, August 9th. BidaskClub cut Celldex Therapeutics from a sell rating to a strong sell rating in a report on Monday, July 24th. Zacks Investment Research cut Celldex Therapeutics from a buy rating to a sell rating in a report on Monday, July 17th. Finally, Aegis reiterated a buy rating on shares of Celldex Therapeutics in a report on Thursday, June 29th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $7.32.

Celldex Therapeutics (CLDX) traded up 3.31% during mid-day trading on Tuesday, reaching $2.81. The company’s stock had a trading volume of 1,189,194 shares. Celldex Therapeutics has a 12 month low of $2.20 and a 12 month high of $5.02. The company’s market cap is $360.64 million. The stock’s 50 day moving average is $2.49 and its 200 day moving average is $2.83.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.05. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. The firm had revenue of $3.83 million for the quarter, compared to analysts’ expectations of $1.21 million. During the same quarter last year, the business earned ($0.32) earnings per share. The company’s revenue was up 175.5% compared to the same quarter last year. Equities research analysts predict that Celldex Therapeutics will post ($1.04) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://ledgergazette.com/2017/09/27/celldex-therapeutics-inc-cldx-given-buy-rating-at-cantor-fitzgerald.html.

Institutional investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. raised its position in Celldex Therapeutics by 26.2% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 6,000 shares during the last quarter. BB&T Securities LLC acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at approximately $117,000. Voya Investment Management LLC raised its position in Celldex Therapeutics by 17.4% in the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 7,499 shares during the last quarter. Overbrook Management Corp acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at approximately $139,000. Finally, Pacad Investment Ltd. acquired a new stake in Celldex Therapeutics in the 2nd quarter valued at approximately $150,000. 56.69% of the stock is currently owned by institutional investors and hedge funds.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply